Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors.
Wang, L., Stanley, M., Boggs, J.W., Crawford, T.D., Bravo, B.J., Giannetti, A.M., Harris, S.F., Magnuson, S.R., Nonomiya, J., Schmidt, S., Wu, P., Ye, W., Gould, S.E., Murray, L.J., Ndubaku, C.O., Chen, H.(2014) Bioorg Med Chem Lett 24: 4546-4552
- PubMed: 25139565 
- DOI: https://doi.org/10.1016/j.bmcl.2014.07.071
- Primary Citation of Related Structures:  
4U43, 4U44, 4U45 - PubMed Abstract: 
MAP4K4 has been shown to regulate key cellular processes that are tied to disease pathogenesis. In an effort to generate small molecule MAP4K4 inhibitors, a fragment-based screen was carried out and a pyrrolotriazine fragment with excellent ligand efficiency was identified. Further modification of this fragment guided by X-ray crystal structures and molecular modeling led to the discovery of a series of promising compounds with good structural diversity and physicochemical properties. These compounds exhibited single digit nanomolar potency and compounds 35 and 44 achieved good in vivo exposure.
Organizational Affiliation: 
Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.